@article{wiloch_enomoto_smith_baynes_messenger_2024, title={Pharmacokinetics of intranasal and intramuscular flunixin in healthy grower pigs}, ISSN={["1365-2885"]}, DOI={10.1111/jvp.13426}, abstractNote={Abstract}, journal={JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS}, author={Wiloch, Emily E. and Enomoto, Hiroko and Smith, Lilly and Baynes, Ronald E. and Messenger, Kristen M.}, year={2024}, month={Jan} }
 @article{elliot_enomoto_petritz_crespo_yeatts_fricke_singleton_thomson_baynes_2024, title={Pharmacokinetics of intravenously and trans-dermally administered fluralaner in healthy laying shaver hens: fluralaner in chickens}, volume={103}, ISSN={["1525-3171"]}, DOI={10.1016/j.psj.2023.103362}, abstractNote={Ectoparasite infestations negatively affect both backyard and commercial chicken flocks in the US. Fluralaner is an isoxazoline shown to be efficacious in treating mite and bed bug infestations in poultry. Fluralaner is approved to treat fleas and ticks in dogs and cats in the US and to treat mite infestations of chickens in Europe and Australia; however, the use of fluralaner in poultry is not yet approved in the US. This study aimed to investigate the plasma fluralaner pharmacokinetic profile of intravenous and transdermal routes and apparent bioavailability of fluralaner administered trans-dermally in healthy shaver hens. A total of 12 individually housed healthy shaver hens received a single dose of either intravenous technical grade fluralaner at 0.5 mg/kg, or transdermal fluralaner (Bravecto® (fluralaner transdermal solution) for dogs, 280 mg/mL, Merck Animal Health) at mean 58.7 mg/kg. Plasma from each hen was collected from the jugular, ulnar or medial metatarsal vein at multiple intervals. Fluralaner concentrations in plasma were determined using Ultra Performance Liquid Chromatography with Mass Spectrometry (UPLC/MS). Non-compartmental analysis revealed that the geometric mean elimination half-life for intravenous and transdermal routes were 80.5 and 179.6 hours, respectively. The geometric mean apparent bioavailability of transdermal routes was estimated as 3.4 %. Prolonged fluralaner concentration in plasma above minimum inhibitory concentration of bed bugs following the single dose was observed in healthy shaver hens for both routes. It is important to understand the pharmacokinetic profile could be useful in determining the appropriate treatment strategy.}, number={3}, journal={POULTRY SCIENCE}, author={Elliot, Baxter A. and Enomoto, Hiroko and Petritz, Olivia and Crespo, Rocio and Yeatts, James and Fricke, Isabel and Singleton, Abby and Thomson, Andrea and Baynes, Ronald E.}, year={2024}, month={Mar} }
 @article{enomoto_elliot_petritz_crespo_yeatts_sheela_fricke_singleton_thomson_baynes_2024, title={Residue, distribution and depletion of fluralaner in egg following a single intravenous and transdermal administration in healthy shaver hens: fluralaner residue in egg}, volume={103}, ISSN={["1525-3171"]}, url={https://doi.org/10.1016/j.psj.2024.103843}, DOI={10.1016/j.psj.2024.103843}, abstractNote={The demand for the use of fluralaner in an extra label manner is increasing due to lack of efficacious treatment to combat mites and bed bugs in the poultry industry in the United States. Fluralaner residue data in eggs is lacking and residues might cause risks to human health. The present study aimed to determine the depletion profiles of fluralaner in eggs and estimate the drug withdrawal interval in whole eggs by adopting the US Food and Drug administration tolerance limit method with single intravenous (0.5 mg/kg) or transdermal administration (average 58.7 mg/kg) in healthy shaver hens. Hens were treated intravenously or trans-dermally with fluralaner. The eggs were collected daily for 28 days for intravenous treated and for 40 days from the transdermal route group. Fluralaner concentrations in yolk and albumen were determined by mass spectrometry. The greater percentage of fluralaner was observed in yolk when compared to the albumen for both administration routes. Non-compartmental analysis was used to calculate the pharmacokinetic parameters in yolk, albumen and whole egg. The longest apparent half-life confirmed in yolk was 3.7 days for intravenous and 14.3 days for the transdermal route. The withdrawal intervals in whole egg for fluralaner following the intravenous and transdermal administration were 7 days and 81 days, respectively, with maximum residue limits (1.3 µg/g) at 13 days and 171 days, respectively, based on the limit of quantification (0.4 µg/g) from the analytical assay reported by EMA and APVMA.}, number={7}, journal={POULTRY SCIENCE}, author={Enomoto, Hiroko and Elliot, Baxter A. and Petritz, Olivia A. and Crespo, Rocio and Yeatts, James and Sheela, Farha Ferdous and Fricke, Isabel and Singleton, Abby and Thomson, Andrea and Baynes, Ronald E.}, year={2024}, month={Jul} }
 @article{petritz_enomoto_meyer_thomson_baynes_flammer_2023, title={Pharmacokinetics and Safety of Sulfamethoxazole-Trimethoprim After Oral Administration of Single and Multiple Doses to Rhode Island Red Chickens (<i>Gallus gallus domesticus</i>)}, volume={37}, ISSN={["1938-2871"]}, DOI={10.1647/22-00020}, abstractNote={Abstract: Sulfamethoxazole-trimethoprim (SMZ-TMP), a commonly prescribed antibiotic for backyard hens, is neither Food and Drug Administration approved nor prohibited in laying hens in the United States. The aim of this study was to determine whether plasma concentrations above targeted minimum inhibitory concentration breakpoint values for Enterobacteriaceae could be achieved with oral dosing. Five Rhode Island red hens (Gallus gallus domesticus) were administered a single dose of 96 mg/kg SMZ-TMP (80 mg/kg SMZ and 16 mg/kg TMP) IV followed by the same dose orally after a washout period. Following oral dosing, mean SMZ concentrations exceeded the target breakpoint for approximately 12 hours; however, TMP only briefly exceeded the target breakpoint. Bioavailability was 60.5% for SMZ and 82.0% for TMP. Ten naïve birds were allocated into control (n = 4) and treatment (n = 6) groups for a 7-day multi-dose study. Treatment birds received an oral suspension dosed at 16 mg/kg TMP and 80 mg/kg SMZ every 48 hours (on days 1, 3, 5, and 7); TMP tablets were additionally dosed at 25 mg/bird on days 1, 3, 5, and 7, and 50 mg/bird on days 2, 4, and 6. Plasma SMZ-TMP concentrations were measured on a multiple time interval by ultraperformance liquid chromatography–mass spectrometry, and pharmacokinetic analyses were performed using a noncompartmental model. No accumulation for either drug was noted following repeated dosing, and no statistical differences in biochemical values, packed cell volumes, or weight were found between pre- and posttreatment in either the treatment or control groups. Sulfamethoxazole (80 mg/kg q48h PO) and TMP (24.1–28.0 mg/kg q24h PO) maintained therapeutic plasma concentrations at or exceeding the minimum inhibitory concentration breakpoint of Enterobacteriaceae for 72 and 24 hours for TMP and SMZ, respectively, without evidence of adverse effects or drug accumulation. Further studies are needed to refine this dosage regimen and evaluate adverse effects in ill birds.}, number={1}, journal={JOURNAL OF AVIAN MEDICINE AND SURGERY}, author={Petritz, Olivia A. and Enomoto, Hiroko and Meyer, Emma G. and Thomson, Andrea and Baynes, Ronald E. and Flammer, Keven}, year={2023}, month={Mar}, pages={1–12} }
 @article{gonzalez-morales_thomson_yeatts_enomoto_haija_santangelo_petritz_crespo_schal_baynes_2023, title={Pharmacokinetics of fluralaner as a systemic drug to control infestations of the common bed bug, <i>Cimex lectularius</i>, in poultry facilities}, volume={16}, ISSN={["1756-3305"]}, url={https://doi.org/10.1186/s13071-023-05962-3}, DOI={10.1186/s13071-023-05962-3}, abstractNote={Abstract}, number={1}, journal={PARASITES & VECTORS}, author={Gonzalez-Morales, Maria A. and Thomson, Andrea E. and Yeatts, James and Enomoto, Hiroko and Haija, Ahmed and Santangelo, Richard G. and Petritz, Olivia A. and Crespo, Rocio and Schal, Coby and Baynes, Ronald}, year={2023}, month={Sep} }
 @article{papich_madsen_messenger_enomoto_2022, title={Ceftazidime pharmacokinetics in dogs after intravenous injection and delivered with the RxActuator Mini-Infuser infusion pump}, volume={5}, ISSN={["1476-4431"]}, url={https://doi.org/10.1111/vec.13205}, DOI={10.1111/vec.13205}, abstractNote={Abstract}, journal={JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE}, author={Papich, Mark G. and Madsen, Melanie and Messenger, Kristen and Enomoto, Hiroko}, year={2022}, month={May} }
 @article{werners_karasek_butler_yeatts_enomoto_baynes_2022, title={Control of ticks on horses using abamectin-impregnated ear tags. A pharmacokinetic and pharmacodynamic study}, ISSN={["1365-2885"]}, DOI={10.1111/jvp.13084}, abstractNote={Abstract}, journal={JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS}, author={Werners, Arno and Karasek, Inga and Butler, Catherine and Yeatts, James and Enomoto, Hiroko and Baynes, Ronald}, year={2022}, month={Jun} }
 @article{madsen_enomoto_messenger_papich_2022, title={Effects of housing environment on oral absorption of acetaminophen in healthy Beagles}, volume={83}, ISSN={["1943-5681"]}, DOI={10.2460/ajvr.21.06.0075}, abstractNote={Abstract}, number={1}, journal={AMERICAN JOURNAL OF VETERINARY RESEARCH}, author={Madsen, Melanie and Enomoto, Hiroko and Messenger, Kristen and Papich, Mark G.}, year={2022}, month={Jan}, pages={80–85} }
 @article{enomoto_love_madsen_wallace_messenger_2022, title={Pharmacokinetics of intravenous, oral transmucosal, and intranasal buprenorphine in healthy male dogs}, ISSN={["1365-2885"]}, DOI={10.1111/jvp.13056}, abstractNote={Abstract}, journal={JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS}, author={Enomoto, Hiroko and Love, Lydia and Madsen, Melanie and Wallace, Amber and Messenger, Kristen M.}, year={2022}, month={Apr} }
 @article{southern_long_barnes_enomoto_messenger_2022, title={Preliminary evaluation of the effects of grapiprant compared with carprofen on acute pain and inflammation following ovariohysterectomy in dogs}, volume={83}, ISSN={["1943-5681"]}, DOI={10.2460/ajvr.21.10.0162}, abstractNote={Abstract}, number={7}, journal={AMERICAN JOURNAL OF VETERINARY RESEARCH}, author={Southern, Brittany L. and Long, Sarah M. and Barnes, Danielle N. and Enomoto, Hiroko and Messenger, Kristen M.}, year={2022}, month={Jul} }
 @article{enomoto_petritz_thomson_flammer_ferdous_meyer_tell_baynes_2021, title={Egg residue and depletion in Rhode Island Red hens (Gallus gallus domesticus) following multiple oral doses of trimethoprim-sulfamethoxazole}, volume={123}, ISSN={["1096-0295"]}, url={https://doi.org/10.1016/j.yrtph.2021.104941}, DOI={10.1016/j.yrtph.2021.104941}, abstractNote={Sulfamethoxazole-Trimethoprim residues in eggs can cause risks to human health. The most common cause of residues in eggs results from failure to meet an appropriate withdrawal interval. The aim of this study was to determine the quantity and duration of sulfamethoxazole-trimethoprim residues in eggs and evaluate the drug elimination parameters in egg components and whole egg to better estimate the withdrawal interval of sulfamethoxazole and trimethoprim following oral administration for 7 days at a purposed dosage regimen (time average 46 mg kg-1 day-1 for sulfamethoxazole, time average 25 mg kg-1 day-1 for trimethoprim). Residues of sulfamethoxazole and trimethoprim in albumen and yolk were analyzed by ultra-performance liquid chromatography mass spectrometry. A greater percentage of sulfamethoxazole was distributed into the albumen (91.53-96.74%) and a greater percentage of trimethoprim was distributed into yolk (63.92-77.36%) during treatment. The residues levels in whole egg declined below or reached the limit of quantification until 13 days for SMZ and TMP respectively. The withdrawal interval for SMZ and TMP were 43 days and 17 days respectively using the FDA tolerance method.}, journal={REGULATORY TOXICOLOGY AND PHARMACOLOGY}, publisher={Elsevier BV}, author={Enomoto, Hiroko and Petritz, Olivia A. and Thomson, Andrea E. and Flammer, Keven and Ferdous, Farha and Meyer, Emma and Tell, Lisa A. and Baynes, Ronald E.}, year={2021}, month={Jul} }
 @article{enomoto_yeatts_carbajal_krishnan_madan_laumas_blikslager_messenger_2021, title={In vivo assessment of a delayed release formulation of larazotide acetate indicated for celiac disease using a porcine model}, volume={16}, ISSN={["1932-6203"]}, DOI={10.1371/journal.pone.0249179}, abstractNote={There is no FDA approved therapy for the treatment of celiac disease (CeD), aside from avoidance of dietary gluten. Larazotide acetate (LA) is a first in class oral peptide developed as a tight junction regulator, which is a lead candidate for management of CeD. A delayed release formulation was tested in vitro and predicted release in the mid duodenum and jejunum, the target site of CeD. The aim of this study was to follow the concentration versus time profile of orally administered LA in the small intestine using a porcine model. A sensitive liquid chromatography/tandem mass spectrometry method was developed to quantify LA concentrations in porcine intestinal fluid samples. Oral dosing of LA (1 mg total) in overnight fasted pigs resulted in time dependent appearance of LA in the distal duodenum and proximal jejunum. Peak LA concentrations (0.32–1.76 μM) occurred at 1 hour in the duodenum and in proximal jejunum following oral dosing, with the continued presence of LA (0.02–0.47 μM) in the distal duodenum and in proximal jejunum (0.00–0.43 μM) from 2 to 4 hours following oral dosing. The data shows that LA is available in detectable concentrations at the site of CeD.}, number={4}, journal={PLOS ONE}, author={Enomoto, Hiroko and Yeatts, James and Carbajal, Liliana and Krishnan, B. Radha and Madan, Jay P. and Laumas, Sandeep and Blikslager, Anthony T. and Messenger, Kristen M.}, year={2021}, month={Apr} }